Frontage expands US–China clinical footprint to meet demand for early phase integration
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.